Search Results
Your search for ,maY matches 16623 pages
Showing 10751 - 10800Meeting the Needs of Older Adults With Cancer
I have served as a patient advocate in many different ways since I was diagnosed with breast cancer in October 2000. For many years, my advocacy was focused on issues related to breast cancer. Since 2012, I have also been engaged in identifying and meeting the needs of the rapidly growing...
Development and Validation of a Quality Assurance Score for Robot-Assisted Radical Cystectomy
What are the factors that add up to the best outcomes for patients who have surgery to treat cancer? Looking for a better way to measure quality of care and share best practices in surgical oncology, a team from Roswell Park Cancer Institute developed a quality assessment tool and validated it in a ...
Talking to Children With Cancer: Sometimes Less Is More
I still remember the day I met Kensie. It was Valentine’s Day. I had sneaked out of the hospital to get my wife a Valentine’s Day card, taking my place among scores of other husbands and boyfriends in front of the rapidly emptying rack of cards. As I started browsing, my beeper sounded. It was the ...
Diagnosing and Managing Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced peripheral neuropathy is a common side effect of cancer treatment—the incidence is reported to be as high as 70% in the first month of chemotherapy1—and can cause significant disability in patients. The extent of the neurotoxicity incurred by patients varies depending on the...
Forging Collaboration Between Children’s and Adult Oncology Groups in Designing Trials for Adolescents and Young Adults
Nonrhabdomyosarcoma soft-tissue sarcomas account for about 5% of all childhood malignancies and are also diagnosed in adolescents and young adults, as well as in older adults, and can require different approaches to treatment based on a patient’s age and stage of disease. These sarcomas comprise...
Cardio-oncology in the Geriatric Patient
As cancer therapies improve and the population as a whole increases, there are rising numbers of elderly patients with cancer. More than half of patients newly diagnosed with cancer are aged 65 years or older.1 In January 2012, it was estimated that more than 8 million cancer survivors were over...
Atezolizumab in Previously Treated Metastatic NSCLC
On October 18, 2016, the anti–PD-L1 (programmed cell death ligand 1) antibody atezolizumab (Tecentriq) was approved for the treatment of metastatic non–small cell lung cancer (NSCLC) progressing during or following platinum-containing chemotherapy.1,2 Patients with epidermal growth factor receptor ...
As More Biosimilars Move Toward U.S. Market, Questions Remain About Cost Savings and Uptake by Physicians and Patients
The U.S. Food and Drug Administration (FDA) approved its first biosimilar drug, filgrastim-sndz (Zarxio), in 2015, allowing it to compete with the granulocyte colony-stimulating factor filgrastim (Neupogen) to treat neutropenia in chemotherapy patients. So far, filgrastim-sndz is the only...
Ellen and Gary Davis Immune Monitoring Core Established at Weill Cornell Medicine
With the goal of advancing a powerful cancer treatment strategy that uses immune cells to fight the disease, benefactors Ellen and Gary Davis have made a $2 million gift to Weill Cornell Medicine to drive ongoing research in immunotherapy, the institution announced. This gift will launch the Ellen...
Florida Atlantic University Appoints Phillip M. Boiselle, MD, as Dean of the Charles E. Schmidt College of Medicine
Florida Atlantic University has named Phillip M. Boiselle, MD, as the new Dean of the Charles E. Schmidt College of Medicine. Dr. Boiselle, who currently serves as Associate Dean for Academic and Clinical Affairs and Professor of Radiology at Harvard Medical School, and is a member of the...
Study Looks for Optimal Dosing of Single-Agent Ipilimumab in Metastatic Melanoma
There has been debate as to the optimal dose of single-agent ipilimumab (Yervoy) in metastatic melanoma. A phase III study presented at the 2016 European Society for Medical Oncology (ESMO) Congress—the first to directly compare these doses—concluded that 10 mg/kg is more effective, but also more...
Small Study Tests Dual Checkpoint Blockade in High-Risk Stage III Melanoma
As neoadjuvant or adjuvant therapy for stage III melanoma patients with palpable disease, the combination of ipilimumab (Yervoy) plus nivolumab (Opdivo) was shown to be a promising, though also toxic, combination in a phase Ib study reported at the 2016 European Society for Medical Oncology (ESMO) ...
Chemotherapy May Be Avoidable in Some Women With Early-Stage Breast Cancer Based on Clinical and Genomic Risks
In the phase III MINDACT trial reported in The New England Journal of Medicine, Fatima Cardoso, MD, of Champalimaud Clinical Center–Champalimaud Foundation, Lisbon, and colleagues found that adjuvant chemotherapy may be avoidable in women with early-stage breast cancer who are at high clinical...
FDA Grants Accelerated Approval to Olaratumab for Treatment of Advanced Soft-Tissue Sarcoma
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to olaratumab (Lartruvo) in combination with doxorubicin to treat adults with certain types of soft-tissue sarcoma. Olaratumab is approved for use with the FDA-approved chemotherapy drug doxorubicin for the treatment...
Is Observation Without Surgery a Viable Strategy for Managing Ductal Carcinoma in Situ?
In a spirited debate, abounding with citations of clinical trials and other evidence, but not without humor and mutual respect, E. Shelley Hwang, MD, MPH, and Armando E. Giuliano, MD, reviewed the data and their clinical experience managing ductal carcinoma in situ and reached opposite...
Vaccines May Boost Immune Responsiveness of Pancreatic Tumors
Pancreatic cancer has been notably unresponsive to immunotherapeutic approaches, but a Stand Up 2 Cancer Dream Team believes their research can change that. Team co-leader Elizabeth Jaffee, MD, Deputy Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, ...
1 in 6 Women Diagnosed With Breast Cancer Have a Symptom Other Than a Lump
Around one in six women (17%) diagnosed with breast cancer go to their doctor with a symptom other than a lump—the most commonly reported breast cancer symptom—according to new research presented by Koo et al at the 2016 National Cancer Research Institute (NCRI) Cancer Conference in...
Adult Survivors of Childhood Cancers Report Long-Term Health Issues
Although progress in treatment and supportive care for children with cancer has resulted in improved survival of these patients, some survivors experience ongoing medical conditions from their cancer or its treatment, including poor general health, poor mental health, functional impairment,...
Scientists Are Boosting Immune Responses in Pancreatic Tumors
The successes observed with various immune oncologic treatment approaches have largely bypassed pancreatic cancer, but this may be about to change, based on emerging insights into how and why these tumors evade attacks by T cells. At the 2nd International Cancer Immunotherapy Conference, two...
Combination Strategies Harness the Power of the Oncolytic Virus Talimogene Laherparepvec
The injectable oncolytic immunotherapy talimogene laherparepvec (also known as T-VEC, Imlygic) may become a valuable component of combination immunotherapy approaches in melanoma, a strategy believed to help overcome resistance of tumors to single-agent immunotherapies. “[Talimogene laherparepvec] ...
Better Quality of Life Reported in Patients With Head and Neck Cancer Receiving Nivolumab vs Chemotherapy
Standard treatment for advanced head and neck cancer—including chemotherapy and radiation—causes painful side effects that impair quality of life, as well as the ability to socialize and engage in daily life activities. A new study of patients with platinum-refractory recurrent, metastatic head...
Preliminary Data Indicate Potential Role for Dabrafenib as Part of Therapy for Pediatric Low-Grade Gliomas With BRAF V600 Mutation
About 10% of children with low-grade gliomas have the BRAF V600E mutation, and preliminary studies suggest that the BRAF inhibitor dabrafenib (Tafinlar) may play an important role in treating this group of patients. A phase I/II trial presented at the 2016 European Society for Medical Oncology...
Second Opinions From Urologists for Prostate Cancer: Do They Make a Difference?
A new analysis indicates that many men with prostate cancer obtain second opinions from urologists before starting treatment, but surprisingly, second opinions are not associated with changes in treatment choice or improvements in perceived quality of prostate cancer care. Published by...
Gut Microbes Linked to Immunotherapy Response in Patients With Melanoma
Patients with malignant melanoma are more likely to respond to immunotherapy treatment if they have greater diversity in their gut bacteria, according to new research presented by Wargo et al at the National Cancer Research Institute's (NCRI) Cancer Conference in Liverpool, United Kingdom....
Expert Point of View: Jean-Charles Soria, MD, PhD
A number of lung cancer specialists were anxious to comment on the positive findings of KEYNOTE-024 and were equally perplexed about the negative results of CheckMate-026. All agreed that the overall survival benefit makes pembrolizumab (Keytruda) a game-changer for the first-line treatment of...
Pembrolizumab, but Not Nivolumab, Improves Outcomes in Front-Line Setting for PD-L1–Positive Advanced NSCLC
Checkpoint inhibitors have revolutionized the treatment of advanced non–small cell lung cancer (NSCLC), but evidence of their benefit was restricted to the second-line setting. However, early-phase trials with both pembrolizumab (Keytruda) and nivolumab (Opdivo) demonstrated favorable results in...
Researchers Reveal Genomic Landscape of Core-Binding Factor Acute Myeloid Leukemia
An international team of researchers from the St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project has completed a detailed map of the genomic landscape for core-binding factor acute myeloid leukemia (CBF-AML). The work reveals differences in the...
Mammography Outcomes Improve When Physicians Compare Prior Screenings
The recall rate of screening mammography is reduced when radiologists compare with more than one prior mammogram, according to a recent study by Hayward et al in American Journal of Roentgenology. “Our findings suggest that radiologists who make comparisons with more than one prior...
7 Substances Added to HHS 14th Report on Carcinogens
The release of the U.S. Department of Health and Human Services (HHS) 14th Report on Carcinogens on November 3, 2016, included 7 newly reviewed substances, bringing the cumulative total to 248 listings. The chemical trichloroethylene (TCE), the metallic element cobalt, and cobalt compounds...
Pembrolizumab Plus Chemotherapy Improves Outcomes Over Chemotherapy Alone in Advanced NSCLC
Combining immunotherapy with a standard chemotherapy doublet appears to be an attractive option for the front-line treatment of advanced nonsquamous non–small cell lung cancer (NSCLC), according to the results of a phase II study presented at the 2016 European Society for Medical Oncology (ESMO)...
Expert Point of View: Axel Bex, MD, PhD
The formal discussant of this trial, Axel Bex, MD, PhD, of The Netherlands Cancer Institute in Amsterdam, was cautious in interpreting these results to be practice-changing. “I congratulate the investigators for the first-ever positive trial for adjuvant treatment of renal cell carcinoma,” he...
Cabozantinib Improves Progression-Free Survival and Response Rates vs Sunitinib in First-Line Treatment of Metastatic Kidney Cancer
Cabozantinib (Cabometyx) improved progression-free survival and response rates in patients with untreated metastatic renal cell carcinoma compared with the standard of care, sunitinib (Sutent), according to the results of a phase II multicenter randomized trial called CABOSUN reported at the 2016...
New Data Suggest Changes Needed to Guidelines for Determining Prognosis in Patients With Thyroid Cancer
A study from the Duke Cancer Institute (DCI) has found a lack of statistical evidence to support the current practice of treating thyroid cancer patients under age 45 differently from those 45 and older. The study, published recently by Adam et al in the Journal of Clinical Oncology,...
How ASCO Is Preparing Members for MACRA
On October 14, 2016, the Centers for Medicare & Medicaid Services (CMS) announced its final policy on what physicians need to do to begin implementing the Quality Payment Program outlined in the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). The Quality Payment Program is a...
Notable Gains in Survival Achieved With Atezolizumab in Non–Small Cell Lung Cancer
The programmed cell death ligand 1 (PD-L1) inhibitor atezolizumab (Tecentriq) significantly improved overall survival, compared to docetaxel, in previously treated, advanced non–small cell lung cancer (NSCLC), according to preliminary results of the phase III OAK study. The findings are the first...
Study Raises Concerns About Timely Follow-up to Positive Mammogram for the Uninsured
A study by University of North Carolina (UNC) Lineberger Comprehensive Cancer Center researchers has found that younger, uninsured women in North Carolina had higher odds of missing a 60-day window for getting follow-up after an abnormal mammogram, even though research underscores the importance of ...
Ribociclib Granted FDA Priority Review for First-Line Treatment of Hormone Receptor–Positive/HER2-Negative Advanced Breast Cancer
On November 1, the U.S. Food and Drug Administration (FDA) accepted a New Drug Application (NDA) for filing and granted Priority Review for ribociclib (LEE011) as first-line treatment of postmenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2...
Study Shows International Trends in Anal Cancer Incidence Rates
A new American Cancer Society study finds that incidence of anal cancer has been increasing in women or in both men and women in 13 of 18 countries studied, particularly in the Americas, Northern/Western Europe, and Australia. The authors say population-based preventive measures, including human...
Phase III SOLO-2 Trial Shows Significant Progression-Free Survival Benefit From Olaparib Treatment in BRCA-Mutated Metastatic Ovarian Cancer
Positive results were announced on October 26, 2016, from the phase III SOLO-2 trial, designed to determine the efficacy of olaparib (Lynparza) tablets (300 mg twice daily) as a monotherapy for the maintenance treatment of platinum-sensitive, BRCA-mutated relapsed ovarian cancer. Results from the...
Effect of Patient Age on Outcomes in Breast Reconstruction
The most comprehensive study of its kind to date found that older women enjoy the same benefits from breast reconstruction following mastectomy for breast cancer as younger women, without a significant increase in the risk for complications. As with patients across all age groups, the benefits of...
Japanese Trial Finds High Levels of Estrogen in Lung Tissue May Be Related to Synchronous Multiple Lung Adenocarcinoma in Postmenopausal Women
Thanks to advances in medical imaging, the detection rate for synchronous multiple lung adenocarcinoma has been on the rise. Cases of synchronous multiple lung adenocarcinoma in Japanese women have been on the rise, despite having a national smoking rate of less than 10% in recent years. This...
Genetic Testing May Be Beneficial in Identifying Patients With Breast Cancer at High Risk for Venous Thromboembolism
Venous thromboembolism is a serious—and sometimes fatal—complication of cancer and chemotherapy treatment. Since breast cancer is one of the most common cancers, it accounts for a large number of cancer-related cases of venous thromboembolism. Routine thromboprophylaxis, however, is not ...
Potential Link Between Androgen-Deprivation Therapy for Prostate Cancer and Risk for Dementia
In a single-center analysis reported in JAMA Oncology, Nead et al found that the use of androgen-deprivation therapy for prostate cancer was associated with an increased risk for dementia. The study involved electronic medical record data from the Stanford University Health System from 1994 to...
Sexual Pain Experienced by Women After Cancer Is Common and May Be Ignored
Painful sex in women after cancer treatment is relatively common, often treatable, and needs to be addressed by medical providers, a University of California (UC), Davis, oncologist and researcher suggests. Vanessa Kennedy, MD, a gynecologic oncologist at UC Davis Health System, said that with...
Prolonged Length of Stays, Readmissions, and Discharge to Care Facilities Among Postoperative Patients With Advanced Cancer
Patients with disseminated advanced cancer who undergo surgery are far more likely to endure long hospital stays and readmissions, referrals to extended care facilities, and death, University of California (UC) Davis researchers have found. Their study, published by Bateni et al in PLOS One,...
Evaluating the FDA’s Approach to Cancer Clinical Trials
Since the announcement of the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) on June 29, 2016, as part of the White House’s Cancer Moonshot, we’ve been working to further the FDA’s efforts to get new oncology products into the hands of patients. We are committed to...
Venetoclax Monotherapy Safe and Clinically Active in Acute Myelogenous Leukemia
A phase II study has found venetoclax (Venclexta) to be clinically active in patients with high-risk relapsed/refractory acute myelogenous leukemia (AML) or those unfit for intensive chemotherapy, with an overall response rate of 19% and a tolerable safety profile. The study results, which were...
Genetic Characteristics of Recurrent and Metastatic Head and Neck Cancers
Next-generation sequencing of recurrent or metastatic head and neck tumors at Memorial Sloan Kettering Cancer Center (MSK) has provided insight into the molecular characteristics of these tumors, which may aid in the implementation of precision treatment. Luc G. Morris, MD, MSc, of Memorial Sloan...
Key Guideline Recommendations
Human papillomavirus (HPV) DNA testing is recommended in all resource settings; visual inspection with acetic acid (VIA) may be used in the basic setting as a “stepping stone” that helps build health service capacity until HPV testing becomes available. Although cotesting with HPV and Papanicolaou...
Study Finds African American Cancer Survivors More Likely to Experience Lasting Debt Related to Cancer and Its Treatment
African American cancer survivors are more likely than whites to experience lasting debt or forgo necessary medical care as they struggle with the financial burden of cancer, whereas white cancer survivors are somewhat more likely to use existing assets to pay for their cancer care, according to a...
